Literature DB >> 20402382

Olopatadine nasal spray for the treatment of allergic rhinitis.

Peter S Roland1, Bradley F Marple, G Michael Wall.   

Abstract

Olopatadine hydrochloride nasal spray (Patanase Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20402382     DOI: 10.1586/eci.09.89

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  1 in total

1.  Investigation of the antiallergic activity of olopatadine on rhinitis induced by intranasal instillation of antigen in sensitized rats using thermography.

Authors:  Tadafumi Tamura
Journal:  Asia Pac Allergy       Date:  2011-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.